ChemotherapyFDA-approvedFirst-line
FOLFIRINOX
How it works
FOLFIRINOX is a combination of four chemotherapy drugs: fluorouracil, leucovorin, irinotecan, and oxaliplatin. These drugs work together to interfere with DNA synthesis and cell division, causing cancer cells to die.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that FOLFIRINOX can improve overall survival in patients with pancreatic cancer, with a median survival of approximately 11.1 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| FOLFIRINOX Chemotherapy for Advanced Pancreatic Cancer: Balancing Benefits and Harms | Pancreatic Cancer | phase-2 | Amongst the 66 patients who completed ≥ 4 cycles, 52 (79%) achieved disease control at FOLFIRINOX completion. | Source → |
| Germline Mutations Affect Pancreatic Cancer Treatment | Pancreatic Cancer | observational | Median progression-free survival was significantly longer in germline-positive patients (10.6 months) compared to germline-negative patients (5.3 months). | Source → |
| Combining Salmonella-IL2 with Chemotherapy for Stage IV Pancreatic Cancer | Pancreatic Cancer | phase-2 | Those patients who received more than five doses of Salmonella-IL2 with FOLFIRINOX had a median progression-free survival of 15 months and a median overall survival of 20.3 months. | Source → |
| Pancreatic Cancer Study Compares First-Line Treatments | Pancreatic Cancer | observational | Median OS was 14.5 months with FFX, 12.4 months with GN, 7.9 months with Gem, and 9.2 months with others. | Source → |
| Triweekly FOLFIRINOX Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median overall survival was 14.2 months, and the median progression-free survival was 6.7 months. | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.